Abstract
This study summarizes the significance of microRNA-134 (miRNA-134) in the pathophysiology, diagnosis, and treatment of depression, a disease still under investigation due to its complexity. miRNA-134 is an endogenous short non-coding RNA that can bind to the 3' untranslated region (3'UTR) of miRNA-134, inhibiting gene translation and showing great potential in the regulation of mood, synaptic plasticity, and neuronal function. This study included 15 articles retrieved from four English-language databases: PubMed, Embase, The Cochrane Library, and Web of Science, and three Chinese literature databases: CNKI, Wanfang, and Chinese Science and Technology Periodical Database (VIP).We evaluated each of the 15 articles using the Critical Appraisal Skills Program (CASP) tool.The standard integrates analyzes of genomic, transcriptomic, neuroimaging, and behavioral data analyses related to miRNA-134 and depression. A multidimensional framework based on standardized criteria was used for quality assessment. The main findings indicate that miRNA-134 significantly affects synaptic plasticity and neurotransmitter regulation, in particular the synthesis and release of serotonin and dopamine. miRNA-134 shows high sensitivity and specificity as a biomarker for the diagnosis of depression and has therapeutic potential for the targeted treatment of depression. miRNA-134 plays a crucial role in the pathogenesis of depression, providing valuable insights for early diagnosis and the development of targeted therapeutic strategies. This work highlights the potential of miRNA-134 as a focal point for advancing personalized medicine approaches for depression.